Implantation of the device is minimally invasive, requiring no sedation or imaging, and is conducted near the ankle.

Medtronic plc MDT recently received Food and Drug Administration (“FDA”) approval for the minimally invasive implantable tibial neuromodulation (ITNM) Altaviva device. The therapy is inserted near the ...

Bladder leakage is a problem for 60-percent of women. These kinds of incontinence issues can be a big problem, and significantly impact quality of life. Sarah Avrech is a mom of three. She started ...

In September 2025, Medtronic announced it had received FDA approval and launched the Altaviva device, a minimally invasive ...

Kathy Boehm shows where the charger is placed to recharge her implant. The charger can be in a belt or tucked inside her pants. Dr. Tarek Garas Dr. Lindsey Hahn Locating the nearest bathroom when she ...

Medtronic (NYSE: MDT) today reported the first patient treated with its Altaviva neuromodulation device for urge urinary incontinence.

The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks GALWAY, Ireland, Sept. 19, 2025 /PRNewswire ...

The advertiser paid a fee to promote this sponsored article and may have influenced or authored the content. The views expressed in this article are those of the advertiser and do not necessarily ...

Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...

The US Food and Drug Administration (FDA) has approved Medtronic’s Altaviva device, intended for the treatment of urge urinary incontinence. This implantable tibial neuromodulation (ITNM) device ...

The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks Bladder control problems affect an ...